Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet
Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to...
Gespeichert in:
Veröffentlicht in: | BMC research notes 2021-04, Vol.14 (1) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | |
container_title | BMC research notes |
container_volume | 14 |
creator | Mveang Nzoghe, Amandine Leboueny, Marielle Kuissi Kamgaing, Eliane Maloupazoa Siawaya, Anicet Christel Bongho, Eliode Cyrien Mvoundza Ndjindji, Ofilia Padzys, Guy-Stephan Ndeboko, Bénédicte Ategbo, Simon Djoba Siawaya, Joel Fleury |
description | Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon. |
doi_str_mv | 10.1186/s13104-021-05570-3 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A661414720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A661414720</galeid><sourcerecordid>A661414720</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1010-a44aa891454b5bb15cb1bf6b525479bea8668c6513a82d685d8fed483d1d86153</originalsourceid><addsrcrecordid>eNptjF9LwzAUxYMoOKdfwKeAT4KZuW2SZr6V4Z_BYOB0ryNN0hpp09Gk4L69dfqwgdyHc8_hdw5C10AnAFLcB0iBMkITIJTzjJL0BI0g42KwlJ4e_OfoIoRPSgVICSO0nblO97WKzldY-ejIKn9dkVm7Jgn2va5tq9U2OIPJtmujdX5PFa1xNuC9w3nZOT1osPFn5gF_2M5g1zS9d3F3h30bcRwyi3c2XqKzUtXBXv3pGL0_Pb7NXshi-Tyf5QtSAQVKFGNKySkwzgpeFMB1AUUpCp5wlk0Lq6QQUgsOqZKJEZIbWVrDZGrASAE8HaOb391K1XbjfNnGTunGBb3JhQAGLEvoQE3-oYYztnG69bZ0Q35UuD0qDEy0X7FSfQib-XJ9yH4DapJ5AQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mveang Nzoghe, Amandine ; Leboueny, Marielle ; Kuissi Kamgaing, Eliane ; Maloupazoa Siawaya, Anicet Christel ; Bongho, Eliode Cyrien ; Mvoundza Ndjindji, Ofilia ; Padzys, Guy-Stephan ; Ndeboko, Bénédicte ; Ategbo, Simon ; Djoba Siawaya, Joel Fleury</creator><creatorcontrib>Mveang Nzoghe, Amandine ; Leboueny, Marielle ; Kuissi Kamgaing, Eliane ; Maloupazoa Siawaya, Anicet Christel ; Bongho, Eliode Cyrien ; Mvoundza Ndjindji, Ofilia ; Padzys, Guy-Stephan ; Ndeboko, Bénédicte ; Ategbo, Simon ; Djoba Siawaya, Joel Fleury</creatorcontrib><description>Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.</description><identifier>ISSN: 1756-0500</identifier><identifier>EISSN: 1756-0500</identifier><identifier>DOI: 10.1186/s13104-021-05570-3</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Analysis ; Antibodies ; Herd immunity ; Testing ; Viral antibodies</subject><ispartof>BMC research notes, 2021-04, Vol.14 (1)</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Mveang Nzoghe, Amandine</creatorcontrib><creatorcontrib>Leboueny, Marielle</creatorcontrib><creatorcontrib>Kuissi Kamgaing, Eliane</creatorcontrib><creatorcontrib>Maloupazoa Siawaya, Anicet Christel</creatorcontrib><creatorcontrib>Bongho, Eliode Cyrien</creatorcontrib><creatorcontrib>Mvoundza Ndjindji, Ofilia</creatorcontrib><creatorcontrib>Padzys, Guy-Stephan</creatorcontrib><creatorcontrib>Ndeboko, Bénédicte</creatorcontrib><creatorcontrib>Ategbo, Simon</creatorcontrib><creatorcontrib>Djoba Siawaya, Joel Fleury</creatorcontrib><title>Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet</title><title>BMC research notes</title><description>Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Herd immunity</subject><subject>Testing</subject><subject>Viral antibodies</subject><issn>1756-0500</issn><issn>1756-0500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNptjF9LwzAUxYMoOKdfwKeAT4KZuW2SZr6V4Z_BYOB0ryNN0hpp09Gk4L69dfqwgdyHc8_hdw5C10AnAFLcB0iBMkITIJTzjJL0BI0g42KwlJ4e_OfoIoRPSgVICSO0nblO97WKzldY-ejIKn9dkVm7Jgn2va5tq9U2OIPJtmujdX5PFa1xNuC9w3nZOT1osPFn5gF_2M5g1zS9d3F3h30bcRwyi3c2XqKzUtXBXv3pGL0_Pb7NXshi-Tyf5QtSAQVKFGNKySkwzgpeFMB1AUUpCp5wlk0Lq6QQUgsOqZKJEZIbWVrDZGrASAE8HaOb391K1XbjfNnGTunGBb3JhQAGLEvoQE3-oYYztnG69bZ0Q35UuD0qDEy0X7FSfQib-XJ9yH4DapJ5AQ</recordid><startdate>20210420</startdate><enddate>20210420</enddate><creator>Mveang Nzoghe, Amandine</creator><creator>Leboueny, Marielle</creator><creator>Kuissi Kamgaing, Eliane</creator><creator>Maloupazoa Siawaya, Anicet Christel</creator><creator>Bongho, Eliode Cyrien</creator><creator>Mvoundza Ndjindji, Ofilia</creator><creator>Padzys, Guy-Stephan</creator><creator>Ndeboko, Bénédicte</creator><creator>Ategbo, Simon</creator><creator>Djoba Siawaya, Joel Fleury</creator><general>BioMed Central Ltd</general><scope>IOV</scope></search><sort><creationdate>20210420</creationdate><title>Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet</title><author>Mveang Nzoghe, Amandine ; Leboueny, Marielle ; Kuissi Kamgaing, Eliane ; Maloupazoa Siawaya, Anicet Christel ; Bongho, Eliode Cyrien ; Mvoundza Ndjindji, Ofilia ; Padzys, Guy-Stephan ; Ndeboko, Bénédicte ; Ategbo, Simon ; Djoba Siawaya, Joel Fleury</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1010-a44aa891454b5bb15cb1bf6b525479bea8668c6513a82d685d8fed483d1d86153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Herd immunity</topic><topic>Testing</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mveang Nzoghe, Amandine</creatorcontrib><creatorcontrib>Leboueny, Marielle</creatorcontrib><creatorcontrib>Kuissi Kamgaing, Eliane</creatorcontrib><creatorcontrib>Maloupazoa Siawaya, Anicet Christel</creatorcontrib><creatorcontrib>Bongho, Eliode Cyrien</creatorcontrib><creatorcontrib>Mvoundza Ndjindji, Ofilia</creatorcontrib><creatorcontrib>Padzys, Guy-Stephan</creatorcontrib><creatorcontrib>Ndeboko, Bénédicte</creatorcontrib><creatorcontrib>Ategbo, Simon</creatorcontrib><creatorcontrib>Djoba Siawaya, Joel Fleury</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><jtitle>BMC research notes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mveang Nzoghe, Amandine</au><au>Leboueny, Marielle</au><au>Kuissi Kamgaing, Eliane</au><au>Maloupazoa Siawaya, Anicet Christel</au><au>Bongho, Eliode Cyrien</au><au>Mvoundza Ndjindji, Ofilia</au><au>Padzys, Guy-Stephan</au><au>Ndeboko, Bénédicte</au><au>Ategbo, Simon</au><au>Djoba Siawaya, Joel Fleury</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet</atitle><jtitle>BMC research notes</jtitle><date>2021-04-20</date><risdate>2021</risdate><volume>14</volume><issue>1</issue><issn>1756-0500</issn><eissn>1756-0500</eissn><abstract>Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese. One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s13104-021-05570-3</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1756-0500 |
ispartof | BMC research notes, 2021-04, Vol.14 (1) |
issn | 1756-0500 1756-0500 |
language | eng |
recordid | cdi_gale_infotracmisc_A661414720 |
source | DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Analysis Antibodies Herd immunity Testing Viral antibodies |
title | Circulating anti-SARS-CoV-2 nucleocapsid -protein antibodies in an African setting: herd immunity, not there yet |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A48%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20anti-SARS-CoV-2%20nucleocapsid%20-protein%20antibodies%20in%20an%20African%20setting:%20herd%20immunity,%20not%20there%20yet&rft.jtitle=BMC%20research%20notes&rft.au=Mveang%20Nzoghe,%20Amandine&rft.date=2021-04-20&rft.volume=14&rft.issue=1&rft.issn=1756-0500&rft.eissn=1756-0500&rft_id=info:doi/10.1186/s13104-021-05570-3&rft_dat=%3Cgale%3EA661414720%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A661414720&rfr_iscdi=true |